Regeneron and Telix Pharmaceuticals have entered into a strategic collaboration to jointly develop and commercialise next-generation targeted radiopharmaceutical therapies for solid tumours. The agreement marks Regeneron’s formal entry into the expanding radiopharmaceutical space, combining its antibody discovery platform with Telix’s radiopharmaceutical development, manufacturing and supply chain capabilities. Valued at up to US$4.3 B, the deal includes a US$40 M upfront payment to Telix, and a 50/50 cost and profit-sharing structure across four initial therapeutic programmes, reflecting growing industry interest in precision oncology and radioligand therapies.